Cargando…
Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection
Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of leukocytes and increase...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352124/ https://www.ncbi.nlm.nih.gov/pubmed/30658395 http://dx.doi.org/10.3390/jcm8010103 |
_version_ | 1783390756120035328 |
---|---|
author | Kraemer, Marcel Krawczyk, Marcin Noor, Fozia Grünhage, Frank Lammert, Frank Schneider, Jochen G. |
author_facet | Kraemer, Marcel Krawczyk, Marcin Noor, Fozia Grünhage, Frank Lammert, Frank Schneider, Jochen G. |
author_sort | Kraemer, Marcel |
collection | PubMed |
description | Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of leukocytes and increases oxidative stress. In chronic liver diseases, it plays a role in leukocyte infiltration and fibrogenesis. Here, we measured VAP-1 plasma concentration and its SSAO activity in 322 patients with chronic hepatitis C infection and evaluated the association of VAP-1 with fibrosis stages. VAP-1 concentration strongly correlated with liver stiffness and was the second strongest influencing variable after gamma-glutamytransferase (GGT) for liver stiffness in regression analysis. The VAP-1 concentration increased with advancing fibrosis stages and the highest concentrations were found in patients with cirrhosis. According to the receiver operating characteristic (ROC) analysis, a VAP-1 cut-off value of 541 ng/mL predicted histologically confirmed cirrhosis (sensitivity 74%; specificity 72%). SSAO activity correlated only moderately with liver stiffness, showing a relatively small increase in advanced fibrosis. To our knowledge, this is the first study on VAP-1 in chronic hepatitis C infection showing its association with progressive fibrosis. In conclusion, VAP-1 plasma concentration, rather than its SSAO activity, may represent a non-invasive biomarker for monitoring fibrogenesis in patients with chronic hepatitis C infection. |
format | Online Article Text |
id | pubmed-6352124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63521242019-02-01 Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection Kraemer, Marcel Krawczyk, Marcin Noor, Fozia Grünhage, Frank Lammert, Frank Schneider, Jochen G. J Clin Med Article Vascular adhesion protein-1 (VAP-1) is a multifunction protein. While membrane-bound VAP-1 is an adhesion protein, soluble VAP-1 catalyzes the deamination of primary amines through its semicarbazide-sensitive amino oxidase (SSAO) activity. VAP-1 supports the transmigration of leukocytes and increases oxidative stress. In chronic liver diseases, it plays a role in leukocyte infiltration and fibrogenesis. Here, we measured VAP-1 plasma concentration and its SSAO activity in 322 patients with chronic hepatitis C infection and evaluated the association of VAP-1 with fibrosis stages. VAP-1 concentration strongly correlated with liver stiffness and was the second strongest influencing variable after gamma-glutamytransferase (GGT) for liver stiffness in regression analysis. The VAP-1 concentration increased with advancing fibrosis stages and the highest concentrations were found in patients with cirrhosis. According to the receiver operating characteristic (ROC) analysis, a VAP-1 cut-off value of 541 ng/mL predicted histologically confirmed cirrhosis (sensitivity 74%; specificity 72%). SSAO activity correlated only moderately with liver stiffness, showing a relatively small increase in advanced fibrosis. To our knowledge, this is the first study on VAP-1 in chronic hepatitis C infection showing its association with progressive fibrosis. In conclusion, VAP-1 plasma concentration, rather than its SSAO activity, may represent a non-invasive biomarker for monitoring fibrogenesis in patients with chronic hepatitis C infection. MDPI 2019-01-17 /pmc/articles/PMC6352124/ /pubmed/30658395 http://dx.doi.org/10.3390/jcm8010103 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kraemer, Marcel Krawczyk, Marcin Noor, Fozia Grünhage, Frank Lammert, Frank Schneider, Jochen G. Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection |
title | Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection |
title_full | Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection |
title_fullStr | Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection |
title_full_unstemmed | Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection |
title_short | Increased Circulating VAP-1 Levels Are Associated with Liver Fibrosis in Chronic Hepatitis C Infection |
title_sort | increased circulating vap-1 levels are associated with liver fibrosis in chronic hepatitis c infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352124/ https://www.ncbi.nlm.nih.gov/pubmed/30658395 http://dx.doi.org/10.3390/jcm8010103 |
work_keys_str_mv | AT kraemermarcel increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection AT krawczykmarcin increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection AT noorfozia increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection AT grunhagefrank increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection AT lammertfrank increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection AT schneiderjocheng increasedcirculatingvap1levelsareassociatedwithliverfibrosisinchronichepatitiscinfection |